Published • loading... • Updated
AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns
Summary by 247wallst.com
1 Articles
1 Articles
AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns
The post AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns appeared first on 24/7 Wall St.. Quick Read JPMorgan maintains its Overweight rating and $260 price target on AbbVie (ABBV), calling the pullback a buying opportunity as the firm sees upside to consensus estimates backed by strong Skyrizi and Rinvoq momentum, despite near-term headwinds from a $744 million R&D charge and competitive pressure …
·New York, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
